

Special Issue

Drug Candidates for the Treatment of Obesity, 2nd Edition

Message from the Guest Editors

According to the WHO, overweight and obesity have reached an epidemic proportion. It is estimated that one billion people globally will be living with obesity by 2030. This is particularly worrying when considering obesity-related metabolic risks, predisposing people to type 2 diabetes mellitus, cardiovascular diseases, and some types of cancer, among other pathological conditions. In addition, the pharmacological management of obesity has often been ineffective or associated with important side effects, thus representing an enormous challenge to healthcare professionals. Despite all of the harmful health impacts for individuals with obesity, the high costs to treat obesity and its related disorders are also a matter of concern, and, thus, the development of new pharmacological therapies for overweight and obesity control has been addressed. Therefore, this Special Issue is focused on new drug candidates for the prevention and treatment of obesity.

Guest Editors

Dr. Maria Isabel Cardoso Alonso-Vale

Department of Biological Sciences, Institute of Environmental, Chemical and Pharmaceutical Sciences, Federal University of Sao Paulo (UNIFESP), Sao Paulo, Brazil

Dr. Monica Marques Telles

Department of Physiology/Nutrition Physiology Division, Federal University of Sao Paulo (UNIFESP), Sao Paulo, Brazil

Deadline for manuscript submissions

25 August 2025



Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/191823

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us. We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)